MetaCap

Immunome Inc. (IMNM)

NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.69-0.92 (-5.54%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMNM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.63
52-week range
15.55 – 30.06
Day range
15.55 – 16.73
Volume / Avg
1.06M / 1.36M
Beta
—

52-week range

$15.55$30.06

IMNM stock today

Immunome (IMNM) closed at $15.69 on Nov 20, down 5.54% (-$0.92), versus the S&P 500's 3.70% decline. Shares are 47.8% below their 52-week high of $30.06, set on Aug 19, 2026 and 0.9% above the 52-week low of $15.55, near the bottom of the past year's range. IMNM is down 27.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 15.3%.

Immunome has posted a net loss over the last twelve months (EPS of -$2.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immunome

Company profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Clay B. Siegall Ph.D.
Headquarters
Bothell, WA
Employees
267
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Immunome generated $6.9 million in revenue, down 23.2% from fiscal 2024, its first annual decline since 2024. Immunome reported a net loss of $212.4 million, compared with a loss of $293.0 million a year earlier. Operating margin was -3228.8%.

Immunome annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.94M$9.04M$14.02M——
Growth-23.23%-35.50%———
Net income$-212.39M$-292.96M$-106.81M$-36.90M$-24.71M
EPS (diluted)$-2.43$-5.00$-5.38$-3.09$-2.14

Analyst forecast

Forecast

Consensus (17 analysts)

strong_buy

Avg. price target

$35.13+123.90%

  • Strong buy 3
  • Buy 13
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $23.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.76 vs $-0.67
Surprise
-13.43%

IMNM news

All IMNM news

Immunome peers

Health Care sector
IMNM peer companies
CompanyPrice% ChgMarket capCompare
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs IMNM
SEPNSepterna Inc.38.61-1.51%$1.84Bvs IMNM
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs IMNM
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs IMNM
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs IMNM
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs IMNM
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs IMNM
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs IMNM

Indexes, lists and sector

Immunome stock FAQ

What is Immunome's stock price today?

IMNM last traded at $15.69 as of Nov 20, 4:00 PM EST, down 5.54% on the day. Prices are delayed at least 15 minutes.

Who is Immunome's CEO?

Dr. Clay B. Siegall Ph.D. is the chief executive officer of Immunome Inc., which has about 267 employees.

What is the IMNM 52-week high?

The 52-week high for IMNM is $30.06 and the 52-week low is $15.55. The stock is currently 47.8% below its high.

Compare IMNM